Could Gilead Make A Profit From Remdesivir?

Roche’s Tamiflu Was A Pandemic Blockbuster, But COVID-19 Is Different

All being well, Gilead could gain emergency approval for remdesivir by early May - but arriving at a 'reasonable' price and devising rapid access programs will be a major challenge.

Gilead_USA

In just a few days, Gilead Sciences Inc. is expected to reveal data from the first of its two large Phase III studies of remdesivir, a drug which is carrying a huge burden of hope and expectation for its potential in treating COVID-19.

There is some hope that the anti-viral drug could help patients hospitalized with moderate and severe conditions, helping them to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip